RTX Corp (NYSE: RTX), trading at $198.58, carries a 31.9x price-to-earnings multiple that sits well above the 27.1x average for the U.S. aerospace and defense sector and the 24.5x median among its direct peers.
That valuation gap raises an uncomfortable question for prospective buyers: whether a richly priced stock can still deliver meaningful upside, or whether expectations have already run ahead of fundamentals.
The bull case rests heavily on a $340 billion total backlog that represents years of contracted revenue yet to flow through the income statement.
RTX’s Raytheon segment alone holds $289 billion of that figure, backed by a rolling 12-month book-to-bill ratio of 1.77, a metric that signals new orders are arriving significantly faster than existing ones are being fulfilled.
Quarterly contract awards totaling $19.9 billion, spanning weapons programs including Patriot, AMRAAM, AIM-9X, and LTAMDS, underline the sustained institutional demand driving that backlog accumulation.
Adding credibility to the optimistic reading, RTX raised its 2026 sales and earnings guidance for the second consecutive quarter, while S&P lifted the company’s credit rating to A-, signaling improved balance sheet confidence from a major ratings agency.
Analyst consensus on Simply Wall St places RTX’s fair value at $228.83 per share, framing the current price as roughly 13% below that modeled estimate, a view held by 236 investors tracked on the platform.
Yet the earnings-based lens tells a cooler story, with the stock’s 31.9x P/E leaving almost no gap to the calculated fair ratio of 31.6x, meaning there is little buffer if earnings growth disappoints or defense spending priorities shift.
Supply chain bottlenecks represent a tangible operational risk that could slow the conversion of that massive backlog into recognized revenue and compress segment operating margins over the near term.
RTX shares have posted a 4.8% gain over the past seven days, though the 90-day return remains negative at roughly 10.4%, highlighting how volatile sentiment around the stock has been despite the longer-term 14.8% one-year total shareholder return.
Investors weighing the two competing narratives must decide whether the backlog-driven cash flow argument or the earnings-multiple caution deserves more weight as the company works through its multi-year order book.
The 3-year total shareholder return of approximately 2.6 times offers some reassurance about the stock’s longer-run track record, but elevated near-term multiples mean execution on guidance will need to be tight to sustain that momentum.
